Latest news and press releases about Caribou Biosciences, Inc. (CRBU): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally.
Price
| Price | $1.25 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.25 |
| EV / EBITDA | -1.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -89.11% |
| Return on Invested Capital | -86.30% |
| Return on Assets | -72.42% |
| Gross Margin | -129.70% |
| Operating Margin | -1090.90% |
| Net Margin | -1030.42% |
Related companies: AARD · ALLO · ENTA · FHTX · HUMA · IVA · OBIO
Explore sector: Healthcare · Biotechnology
More sections of CRBU: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks